1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
North China Pharmaceutical Company Ltd.

North China Pharmaceutical Company Ltd.

600812.SS
North China Pharmaceutical Company Ltd.CN flagShanghai Stock Exchange
4.64
CNY
+0.05
- -
7.96BMarket Cap
North China Pharmaceutical Company Ltd.
600812.SS
(Shanghai Stock Exchange)

Recent

price

4.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
10
11.95
10
9.11
6.1
4.9
4.9
4.93
5.63
7.05
7.09
6.1
6.12
6.21
5.75
5.4
3.91
Revenue per Share
0.24
0.14
0.02
0.01
0.02
0.04
0.03
0.01
0.09
0.11
0.06
0.01
-0.4
- -
0.07
0.11
0.07
Basic EPS, GAAP
-1.71
-0.85
-1.01
-0.51
-0.11
-0.15
-0.45
-0.07
0.16
0.06
-0.16
0.3
0.27
0.25
0.26
0.37
-0.24
Free Cash Flow per Basic Share
0.21
0.32
0.39
0.32
0.23
0.25
0.27
0.26
0.32
0.38
0.4
0.44
0.43
0.31
0.27
0.24
0.17
Dividend per Share
0.82
0.95
1.19
0.94
1.01
1
0.98
1.03
1.05
1.13
1.15
1.12
0.65
0.67
0.69
0.77
0.8
Book Value per Share
0.82
1.03
3.29
2.59
2.95
2.76
2.66
2.73
2.58
2.56
2.73
2.38
1.72
1.34
1.2
1.1
1.11
Tangible Book Value per Share
1,029
1,026
1,112
1,366
1,541
1,611
1,649
1,563
1,637
1,624
1,622
1,702
1,715
1,630
1,716
1,711
1,689
Basic Weighted Avg Shares
10,287
12,251
11,126
12,438
9,394
7,903
8,082
7,709
9,214
11,457
11,493
10,385
10,500
10,120
9,870
9,242
6,611
Sales/Revenue/Turnover
4.56
-1.05
-1.13
0.99
2.75
3.22
2.96
6.87
7.39
6.92
6.84
6.5
7.41
5.9
7.4
7.2
7.56
Operating Margin (%)
265
286
281
345
407
391
420
449
546
581
620
703
779
878
863
945
- -
Depreciation Expense
242
138
18
14
39
63
54
19
151
172
97
19
-689
5
127
183
126
Net Income, GAAP
27.71
6.58
43.94
60.12
45.42
30.54
33.93
75.76
26.5
36.08
44.03
73.77
- -
68.85
30.62
27.97
26.85
Effective Tax Rate (%)
2.35
1.13
0.16
0.11
0.41
0.8
0.67
0.24
1.64
1.5
0.85
0.18
-6.56
0.05
1.29
1.98
1.91
Profit Margin (%)
-850
-1,763
-407
-1,484
-2,870
-1,364
-2,411
-1,878
-3,348
-2,180
166
-1,528
-3,426
-2,251
-2,702
-4,268
-3,171
Working Capital
2,163
3,071
3,285
3,085
1,491
2,820
1,707
2,475
1,287
2,144
4,899
3,627
2,542
4,380
3,722
2,001
2,976
LT Debt
1,182
1,456
4,178
4,146
5,252
5,270
5,291
5,281
5,512
5,754
7,056
7,017
6,228
6,270
6,675
6,885
6,934
Total Equity
6.75
-1.83
-0.85
0.51
1.42
1.81
1.49
1.12
4.18
3.85
2.64
0.9
- -
1.13
3.01
2.8
1.99
Return on Invested Capital (%)
6.84
4.23
1.74
1.29
2.77
3.91
3.27
1.32
5.22
5.13
3.06
1.04
- -
0.89
2.64
2.65
1.82
Return on Capital (%)
33.31
15.25
1.55
1.05
2.71
3.95
3.36
1.16
9.07
9.7
5.27
0.99
-45.74
0.45
11.18
14.66
9.73
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
9,214
8,260
LT Borrowings
- -
1,877
2,852
LT Finance Leases
- -
124
125
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,716
1,716
Market Capitalization
9,892
9,351
9,189

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
8,131
8,265
Cash, Cash Equivalents & STI
- -
1,541
1,385
Accounts Receivable, Net
- -
2,411
2,604
Inventories
- -
2,411
2,413
Total Current Liabilities
- -
12,399
11,437
Payables & Accruals
- -
- -
- -
ST Debt
- -
9,214
8,260
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.01%
-0.3%
3.15%
Free Cash Flow
-92.4%
-53.05%
42.48%
Net Income, GAAP
-82.59%
-284.17%
44.15%
Sales/Revenue/Turnover
2.08%
-4.2%
-6.36%
Total Cash Common Dividend
1.88%
-7.54%
-11.99%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,558
2,674
2,329
2,309
9,870
2025
2,574
2,701
- -
1,757
9,242
2026
2,153
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.07
2025
0.03
- -
- -
- -
0.11
2026
0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
- -
- -
- -
0.27
2025
0.04
- -
- -
- -
0.24
2026
0.04
- -
- -
- -
- -
Similar Companies
RLS Global AB (publ) (RLS.ST)
Verano Holdings Corp. (VRNOF)
Ilsung Is Co., Ltd. (003120.KS)
Beijing SL Pharmaceutical Co., Ltd. (002038.SZ)
Gnomestar Craft Inc. (GNOM.CN)
Sumitomo Pharma Co., Ltd. (SMDPY)
Business
North China Pharmaceutical Company Ltd (600812.SS) engages in the research, development, production and sales of pharmaceutical products in China and internationally. Founded in 1992 and headquartered in Shijiazhuang, Hebei province, the company offers chemical pharmaceuticals including anti-infectives such as penicillins, cephalosporins, clindamycin phosphate and vancomycin hydrochloride; biotechnology drugs encompassing recombinant human granulocyte colony-stimulating factor, recombinant human erythropoietin biosimilars and recombinant hepatitis B vaccines; cardiovascular and cerebrovascular treatments; immunomodulators; vitamins and nutritional health products like vitamin B6 injections and adenosylcobalamin capsules; biological pesticides; veterinary drugs; and active pharmaceutical ingredients, excipients and finished dosage forms including injections, tablets and powders. It operates primarily in the pharmaceutical industry with over 700 products across anti-infection, cardio-cerebrovascular, anti-tumor, immune regulation, nephropathy and health consumer segments, targeting domestic hospitals, retailers and export markets while maintaining subsidiaries like NCPC Hebei Huamin Pharmaceutical Co Ltd and North China Pharmaceutical Huasheng Co Ltd. Recent developments include securing approvals in 2025 for isavuconazonium sulfate for injection, vitamin B6 injection and other new drugs; obtaining EU GMP certification in March 2025; completing acquisitions of stakes in NCPC Hebei Huamin Pharmaceutical and North China Pharmaceutical Group Aino Co; signing a financial services agreement with Jizhong Energy Group Finance; and announcing its 2025 semi-annual report with operational advancements in biomedicine.